Pliva Pharma Ltd

Vision House, Bedford Road, Petersfield, Hampshire, GU32 3QB
Telephone: +44 (0)1730 710 900
Fax: +44 (0)1730 710 901
Medical Information Direct Line: +44 (0)1730 710 944
Medical Information e-mail: medinfo@pliva-pharma.co.uk
Customer Care direct line: +44 (0)1730 710 910

Summary of Product Characteristics last updated on the eMC: 03/10/2003
SPC Modrasone Cream, Ointment


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Modrasone Cream

Modrasone Ointment


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Alclometasone Dipropionate 0.05% w/w


Go to top of the page
3. PHARMACEUTICAL FORM

Cream/Ointment for topical use.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Alclometasone dipropionate is a non-fluorinated topically active synthetic corticosteroid. Modrasone is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.


Go to top of the page
4.2 Posology and method of administration

Adult and Children:

A thin film of Modrasone should be applied to the affected area two or three times daily or as directed by the physician. Massage gently into the skin until the medication disappears.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any of the ingredients; rosacea; acne and perioral dermatitis; tuberculous and viral lesions of the skin, particularly Herpes Simplex; vaccinia; varicella.

Modrasone should not be used in fungal or bacterial skin infections.


Go to top of the page
4.4 Special warnings and precautions for use

As with all topical steroids, long term continuous therapy should be avoided where possible, particularly in infants and children as adrenal suppression may occur even without occlusion. In infants the napkin may act as an occlusive dressing and thus increase absorption.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Topical administration of corticosteroids to pregnant animals can cause abnormalities in foetal development. The relevance of this finding to human beings has not been established; however, topical steroids should not be used extensively in pregnancy i.e. in large amounts or for long periods.

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Modrasone should be administered to nursing mothers only after careful consideration of the benefit/risk relationship.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

Excessive prolonged use may result in local atrophy of the skin, striae and superficial vascular dilation, particularly on the face.


Go to top of the page
4.9 Overdose

Excessive prolonged use of topical corticosteroids can suppress pituitary-adrenal function resulting in secondary adrenal insufficiency which is usually reversible. In such cases appropriate symptomatic treatment is indicated. In cases of chronic toxicity, corticosteroids should be withdrawn.

The steroid content is so low as to have little or no effect in the unlikely event of accidental oral ingestion.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Alclometasone dipropionate is a non-fluorinated, topically active synthetic corticosteroid. Alclometasone dipropionate suppresses local inflammation at doses producing minimal systemic effects. Studies have shown alclometasone dipropionate to be approximately 2/3 as potent as betamethasone valerate and 60 x as potent as hydrocortisone.


Go to top of the page
5.2 Pharmacokinetic properties

Not applicable in view of topical action and application.


Go to top of the page
5.3 Preclinical safety data

Modrasone appears to be a relatively non-toxic and non-irritating drug product that produces no unusual or unexpected teratologic effects in laboratory animals. A wide margin of safety was demonstrated in all species studied. Acute oral and intraperitoneal doses more than 3,000 times the proposed topical human dose were without any toxicologically significant effects.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Cream:

Propylene Glycol Ph Eur

White Soft Paraffin BP

Cetostearyl Alcohol BP

Glyceryl stearate PEG 100 stearate

Polyoxyethylene (20) cetyl ether

Sodium dihydrogenium phosphate dihydrate

4-Chloro-M-Cresol BP

Phosphoric Acid Ph Eur

Purified Water Ph Eur

Ointment:

Hexylene glycol

Propylene glycol monostearate

White Beeswax BP

White Soft Paraffin BP


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

Cream and Ointment: 60 months


Go to top of the page
6.4 Special precautions for storage

Store below 25°C


Go to top of the page
6.5 Nature and contents of container

Cream and Ointment: Aluminium tubes with white LDPE caps. Pack size: 50g


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable


Go to top of the page
Administrative Data

Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Schering-Plough Ltd

Shire Park

Welwyn Garden City

Hertfordshire

AL7 1TW


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

Cream: PL 0201/0060

Ointment: PL 0201/0061


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

26 March 1995


Go to top of the page
10. DATE OF REVISION OF THE TEXT

5 March 1996

Legal Category POM

Distributed in the UK by: PLIVA Pharma Ltd., Vision House, Bedford Road, Petersfield,

Hampshire GU32 3QB



More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/510/SPC/Modrasone Cream, Ointment/


Active Ingredients/Generics

 
   alclometasone dipropionate


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk